Page 90 - Clinical Olfactory Working Group Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical olfactory working group consensus statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Olfactory Working Group Consensus Statement Today - Breaking & Trending Today

Welcome To IANS Live - NATION - Only 311 of 1.9 mn Covaxin beneficiaries reported side effects: Govt

Photo Credit: IANS
IANSLive
New Delhi, March 11 (IANS) Bharat Biotech s Covaxin has a negligible number of side effects reported among the beneficiaries of the Covid-19 vaccine, NITI Aayog s Member (Health), V.K. Paul said on Thursday.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 11-March-2021 ....

New Delhi , News Service , India Private , Aayog Member Health , Bharat Biotech , All Rights , புதியது டெல்ஹி , செய்தி சேவை , இந்தியா ப்ரைவேட் , ஆயோக் உறுப்பினர் ஆரோக்கியம் , பாரத் பயோடெக் , அனைத்தும் உரிமைகள் , தடுப்பு மருந்துகள் ,

MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Topline data from the Phase 2 HERACLES clinical trial with MaaT013 will be announced near-term
MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic, MaaT013, will be reported in an oral presentation at the virtual 47
th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place from March 14 March 17, 2021. The data was previously presented at the American Society of Hematology in December 2020. MaaT013 is an enema formulation of a full ecosystem microbiota biotherapeutic characterized by a consistent high diversity and richness of microbial species derived from pooled healthy donors The results include data from 29 patients with gastrointestinal, acute Graft-versu ....

United States , Microbiota Biotherapeutic , Kostenloser Wertpapierhandel , Florent Malard , Laura Mittmann , American Society Of Hematology , Sorbonne University , European Medicines Agency , Drug Administration , Trophic Communications , Meeting Of The European Society For Blood , Compassionate Use Expanded Access Treatment Program , Graft Versus Host Disease , Annual Meeting , European Society , Marrow Transplantation , American Society , Associate Professor , Saint Antoine Hospital , On Demand Library , Successful And Safe Treatment Of Intestinal , Expanded Access Treatment Program , Maat Pharma , Orphan Drug Designation , Microbiome Ecosystem Therapies , ஒன்றுபட்டது மாநிலங்களில் ,

Reportable, Inc.: Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers

Reportable, Inc.: Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers
Key Takeaways:
Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.
Scientists at the University of Alberta also published a study showing potential in breast cancer.
PCLX-001 led to significant tumor regression in mouse models, including completely eliminating lymphoma tumors derived from a patient whose cancer had stopped responding to the standard therapies CHOP and Roche s Rituxan.
Click image above to view full announcement. ....

Kostenloser Wertpapierhandel , Roche Rituxan , Luc Berthiaume , University Of Alberta , Alberta Newsfile Corp , University Of Dundee , லூக் பெர்த்தியாம் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , பல்கலைக்கழகம் ஆஃப் டண்டீ ,

Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can

(1)
STOCKHOLM, March 10, 2021 /PRNewswire/
Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC). The trial is designed to complement the ongoing clinical program and subsequently broaden the development of CAN04. The phase Ib trial is planned to be performed in up to 30 patients in France and Spain. The current estimate is to start therapy in the first patient in the end of Q2 2021.
Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both blockade of IL-1 signaling and Antibody-Dependent Cellular Cytotoxicity (ADCC). Preclinical data show that CAN04 can increase the efficacy of chemotherapy. CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with t ....

Antibody Dependent Cellular Cytotoxicity , Nasdaq Stockholm , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,

Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics prepares clinical development program of sevuparin in sepsis/septic shock

(1)
STOCKHOLM, SWEDEN - March 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a clinical development program of its drug candidate sevuparin in patients suffering from sepsis/septic shock, and possibly also other severe inflammatory conditions arising in conjunction with major trauma, surgery, autoimmunity and viral infections. Modus Therapeutics expects to start the first clinical trial in this new indication around the end of 2021. Sevuparin has already demonstrated a favorable safety profile in clinical trials for other indications.
Patients suffering from sepsis are at risk of developing septic shock and multi-organ failure. Septic shock is a leading cause of death in intensive care units, with mortality rates typically exceeding 30 percent. There is currently no specific pharmaceutical treatment available for the treatment of sepsis. As a result, it is one of the costliest conditio ....

Karolinska Institutet , Johan Dighed , Viktor Drvota , Karolinska Development Ab Nasdaq Stockholm , Karolinska Development , Nasdaq Stockholm , Modus Therapeutics , Modus Therapeutic , General Counsel , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் , மோடஸ் சிகிச்சை , ஜநரல் ஆலோசனை ,